Business Description

Yasheng Group is a U.S. company, that conducts business operations in the US, China, and the Philippines in four major segments: Agriculture & Fisheries, Biotechnology, Blockchain, and Mining. The four business segments of Yasheng Group include:

Mining:

Mining Rouge Mountain Mining Group, a United States Arizona corporation with a mine and exploration and development company, is engaged in the acquisition and development of mineral properties, primarily Jade, gold & silver, and other mineral properties (e.g. Copper, Zinc, mines, Montmorillonite, etc.). 1100 acres of mineral placer mining claims to Rouge Mountain Mining Group & possesses 54 claims placer gold mining & rock gold claims situated in LA PAZ County, Arizona. an Arizona corporation (” Rouge Mountain “) Rouge Mountain Mining Group’s subsidiaries Silk Road Mining Company mine an average of 200 tons of jade per year, Jade is a mineral, much used in some cultures as jewelry and for ornaments, Jade processing plant of the Rouge Mountain Mining Group’s uses mined jade to make jade carvings handicrafts artwork, partially supplied and sold to the market and customers

Agriculture:

Yasheng Group is a Colorado corporation U.S. company, is a holding company that operates and conducts its business operations in China., Philippine. The company is a producer of specialty agriculture-based products, specializing in developing organic ecology agriculture by cultivating, processing, marketing, and distributing a range of desert plants and agro-byproducts. Its product portfolio includes perishables and processed foods sold in volume, repackaged into units, or sold directly to consumers in local markets. Main products are divided into Our Desert Wild Plants and agro-byproducts are processed primarily from premium specialty agriculture products grown in Northwest & South China in three agricultural product categories: fresh fruits, specialty crops, and seeds. We have been producing our award-winning premium specialty agriculture products for over 40 years. We use the national transformation of desertification in northwest China to build a green ecological environment and plant over 200,000 acres of large area of desert wild plants. We harvest our crops through a large area of desert plant medicine production base that we agricultural subsidies land and from collective farm operators. Our primary product offering includes over 16 major agriculture products under 4 product categories with the major products including Cistanche herba, seabuckthorn, wolfberry, licorice, Chaihu, ginkgo, shuttle, Betel nut, gastrodia, tea, organic food, etc. Fruit: grape, coconut, mango, etc, Seeds: flax seeds, coffee bean, etc. Seafood: fish, crab, and shrimp. We also produce many additional fresh fruits which supply the local and provincial markets. We have large food-grade cold storage in Shanghai, Guangzhou, and Qingdao. Since Shanghai has the largest international airport and seaport in the world, this gives us the opportunity to conduct direct international transport by air and sea. We supply food to the large Chinese mainland supermarket chain: Vanguard, Walmart, RT_MART Carrefour. We generated approximately 59% of our agriculture products revenues from Herb-Medicine-based products, 1.5% from seeds, 7.5% from fruits, and 12% from Seafood products and the residual from other production during the year ended September 31, 2020.

Biotechnology:

One of the major segments of Biotechnology is a manufacturer and supplier of a series of nutrition and healthcare products. It is a collection of bioengineering, health food, supercritical carbon dioxide extraction, wolfberry, herbal medicine, Hemp seeds, and Songaricum. Ginkgo deep processing products research, and development, is a leading producer of standardized herbal extracts, botanical herb powder, herbal tea bag cuts, and Traditional Chinese Medicals. based on medicals and extracts. our factory has independent research including natural ingredients, Phytochemistry, Analytical R&D, Biological Research, Microbiology, and medical formulations R&D. and synthesis of natural herbs antibodies, reagents, and custom services for biological research in both academia and industry. We can provide competitively priced products and services that support researchers in the areas of peptide synthesis, antibody products, custom antibody services, diagnostic immunology, animal services, and antibody-related bioassay and kit development. Driven by global customers’ requirements, every person at The Maghreb is committed to quality procedures to ensure the traceability of herb raw materials and ingredients which we manufactured. the plant units are ISO, HACCP, Halal, and Kosher certified.

Blockchain:

The world’s first digital betel nut industry public chain is the digital asset-based ecological platform of the betel nut industry built by Yasheng Group & Singapore Antesamamen Foundation based on blockchain technology, with the functions of anti-counterfeiting traceability, boutique mall, supply chain finance, intelligent futures trading, asset confirmation, and chain and so on. Betel nut chain (Betelnut Chain) aims to solve the problems of the betel nut industry system complex and different standards, lack of sustainable business model, asset circulation and financing development, committed to redefining the new standard of global betel nut industry, enabling green and sustainable development of betel nut industry, leading the global betel nut industry into the era of the digital asset blockchain. Through distributed accounting, cross-departmental cooperation and real-time settlement are achieved. Finally, the real assets of betel nut are certified through its quantitative and programmable functions, such as dividends, transfers, repurchases, cancellations, etc. In general, the assets can eliminate the trust problem, reduce the communication cost, deintermediary, reduce the transaction cost, and improve the efficiency of asset circulation. Yasheng Group joint venture company Yongsheng Environmental Technology company is located in the region of 2.3 million betel nut farmers with 300 million trees and acquisition and initial processing enterprises to integrate, through the global betel nut chain (BNC), to the global capital market, Speed up the internationalization of Hainan betel nut. While enhancing the value of betel nut in Hainan, the economic benefits of betel nut growers, purchasing, and initial processing enterprises are increased, which contributes to the construction of the Hainan Free Trade Port and the rural revitalization of Hainan. It can realize the construction and application of agricultural IoT.

Intent for the Raise:

Yasheng Group plans to raise this round for the Biotechnology segment of their company, and more specifically, for Jove Therapeutics. Yasheng Group has entered a Joint Venture with ProMab Biotechnologies, Inc, a leading antibody and cell therapy development company, to form Jove Therapeutics. The purpose of the new venture is to expand tomorrow’s cutting-edge technology for the development of multiple myeloma and other cancer treatment. The Joint Venture takes the stage of powerful cell therapeutics by bridging CAR-T/NK’s gene delivery gaps with mRNA-LNP in cancer therapy.

Jove Therapeutics, a spin-off company from ProMab Biotechnologies, Inc, holds a worldwide (except in China, Europe, and Canada) exclusive license right of a humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic engineered cell therapies, as well as a non-exclusive license of an mRNA-lipid nanoparticle (mRNA-LNP)and NK production technology platform obtained from ProMab Biotechnologies, Inc.

Jove Therapeutics’ lead asset, PMC750NK, is a next-generation allogeneic CAR-NK engineered by the mRNA-LNP system and is derived from PMC750, an extensively validated CAR-T program that targets multiple myeloma. PMC750 has completed its efficacy tests through extensive pre-clinical research, including in-vitro analysis and animal toxicology studies.

Jove Therapeutical’s mission is to expand tomorrow’s cutting-edge technology for the development of multiple myeloma and other cancer treatment. The Joint Venture takes the stage of powerful cell therapeutics by bridging CAR-T/NK’s gene delivery gaps with mRNA-LNP in cancer therapy.

Jove Therapeuticals’s scientific expert team is turning to immunotherapy approaches targeting B cell maturation agent (BCMA), a cell-surface protein expressed by mature B lymphocytes, plasma cells, and most cases of multiple myeloma. BCMA, also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17) binds to several ligands, including BAFF (B cell activating factor) and APRIL (A proliferation-inducing ligand) to mediate cell survival through downstream NF-kappa B and MAPK/JNK signaling pathways. BCMA has been targeted by antibodies and, recently, CAR (chimeric antigen receptor)-expressing T cells. CAR-T cells based on a number of monoclonal antibodies to CD19 (e.g., FMC63, SJ25C) have proven successful in the treatment of B-cell malignancies. Although BCMA CAR-T cells targeting multiple myeloma have been reported, there is a need for clinical trials with novel CAR-T cells to advance the treatment of hematological cancers.

Problem

Multiple myeloma is a cancer of plasma cells characterized by clonal proliferation in the bone marrow microenvironment. Multiple myeloma is the second-most common hematologic malignancy, accounting for 5–10% of all hematologic malignancies in the USA. Despite recent progress in treatment, multiple myeloma remains incurable with high rates of relapsed and refractory disease.

Solution

Jove Therapeutics Inc will expand tomorrow’s cutting-edge technology for the development of multiple myeloma and other cancer treatment. The company takes the stage of powerful cell therapeutics by bridging CAR-T/NK’s gene delivery gaps with mRNA-LNP in cancer therapy.

Jove Therapeutics’ lead asset, PMC750NK, is a next-generation allogeneic CAR-NK engineered by the mRNA-LNP system and is derived from PMC750, an extensively validated CAR-T program that targets multiple myeloma. PMC750 has completed its efficacy tests through extensive pre-clinical research, including in-vitro analysis and animal toxicology studies. These data indicate that novel CAR-T cells utilizing the BCMA 4C8A scFv are effective against multiple myeloma and warrant future clinical development. Jove Therapeutics strongly believes that BCMA CAR-T cells based on the novel mAb significantly decreased multiple myeloma tumor growth, demonstrating great potential for treating patients with multiple myeloma

Business Model

Business Research Models

The use of research models is often a critical part of scientific discovery in the life sciences and is required by FDA guidelines as well as foreign regulatory agencies for new cell therapy drug approval processes. Our business is primarily involved in the early stages of cell therapy drug discovery and development, commonly referred to as the pre-clinical stage of drug development. During this stage, promising new drug candidates are evaluated for their effectiveness and safety through testing in research models. Data from the pre-clinical stage is submitted to the applicable regulatory agency for review in order for the drug to obtain approval to advance to the human testing stage, commonly known as clinical studies. Our research models include humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic engineered cell therapies, as well as a non-exclusive license of an mRNA-lipid nanoparticle (mRNA-LNP)and NK production technology platform which will be first research platform in the cell therapy market., we expect this technology platform will be increasingly demanded by biomedical researchers and pharmaceuticals for specialized cell therapy research and discovery. We focus on maintaining reliable powerful cell therapeutics by bridging CAR-T/NK’s gene delivery gaps with mRNA-LNP in cancer therapy.

As a result, we provide consistent value-added cell therapy candidates’ availability and offer a wide variety of healthy, genetically defined, and specifically targeted research models. We further differentiate our research models by providing extensive technical service and support, including scientific oversight from a team of dedicated professionals

Market Projection

The projected development milestones:
Year: 1
Headcount: 3
Capital Needed (Millions USD): $0.5
Goals to Finish: 1) Start up a manufacturing and R&D facility
2) Complete QA/QC tests and prepare related data.
3) Launch product into US and international markets.

Year 1.5 – 2.5
Headcount: 5-8
Capital Needed (Millions USD): $1.2
Goals to Finish: 1) Continue to push products into the market
2) Establish distribution channels (domestic and international)
3) Launch large marketing campaigns

The following financial projections are based on revenues from only two sources: drug development service and drug candidate out-licensing.

Competition

Our Competitive Strengths

1) Develop Long-Standing Relationships with a growing Customer Base. Our customers will consist primarily of large pharmaceutical companies, biotechnology, hospitals, academic institutions, and government agencies. We will develop long-term, stable relationships with our customers. We will further strengthen our customer relationships by offering related drug candidate pipelines and services to our research model customers.

2) Critical Component of Pharmaceutical Research. The research models are essential to the new drug discovery and development process. While pharmaceutical companies generally invest large sums of money in developing new drugs, the purchase of research models typically represents an immaterial portion of the cost to commercialize a new drug. Our business for high-quality models and consistent product availability enables us to maintain and expand our customer relationships.

3) Experienced and Motivated Management Team. Our senior management team has extensive experience in supplying the biomedical research industry and an average of 10 years of experience with big pharmaceuticals. Our senior management team has successfully grown our business, secured our current strong market positions, integrated eight strategic acquisitions, and positioned us for growth. Our senior management team has broadened our pure research model focus to also include being a leading supplier of biomedical products and services in several specialized niche markets.

Traction & Customers

Jove Therapeuticals Inc: Sales, Marketing, and Customer Support

We sell our pipeline drug candidates with strong IP and services principally through a direct sales force. The direct sales force is supplemented by a network of international distributors for some of our pipeline drug candidates with strong IP and services businesses. Our internal marketing groups support the field sales staff while developing and implementing programs to create close working relationships with customers in the biomedical research industry. Our website will be an effective marketing tool, and we will make it a valuable resource in the laboratory animal field for our clients.

Target #1

Small and mid-size biotech companies in the U.S and worldwide
The initial targets of company businesses are small and mid-size biotech companies, where they do not have their own technology platform and do not have in-house expertise for drug discovery and development.

Target #2

Big pharmaceutical companies
Big pharmaceutical companies such as Pfizer, GSK, Amgen, etc. will be targeted as clients of our novel next-generation CAR-NK pipelines of human diseases, in which we own the IP position of the scientific innovation

Investors

Jove Therapeuticals Inc received over $1 million in research and development funding from Promab Biotechnology Inc. and carried out extensive research objectives

Terms

Yasheng Group is offering a total of 20,000,000 shares at a price of $0.25/share. This is an equity offering with voting rights.

Risks

See Offering Statement; A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature.
These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Neither PicMii Crowdfunding nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.
The information contained herein includes forward-looking statements. These statements relate to future events or future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Equity Security

$44,291,445.8

None

Regulation Crowdfunding – Section 4(a)(6)

August 21, 2023

$1000

$10,000-$5,000,000

*If the sum of the investment commitments does not equal or exceed the minimum offering amount at the offering deadline, no securities will be sold and investment commitments will be cancelled returned to investors.